Gabapentin: The 'Harmless' Nerve Pill Families Should Count
Gabapentin is prescribed for nerve pain and seizures and widely assumed harmless. Here is what the evidence says about misuse, withdrawal, and overdose risk.

Gabapentin: The 'Harmless' Nerve Pill Families Should Count
"It's not a narcotic. The doctor said it was safe."
That sentence comes up in almost every family conversation about gabapentin. It is usually said by someone who loves the person taking it, and it is usually said with relief — because after opioids, or after a year of watching a medicine cabinet, a drug that is not a narcotic feels like a small victory.
The sentence is half right, and the half that is wrong matters. Gabapentin is not an opioid. It is not a benzodiazepine. It does not carry a federal controlled-substance schedule. And it is also a medication that is misused, diverted, sold on the street, taken in doses far above what any prescriber intended, associated with withdrawal when stopped abruptly, and involved in a growing share of overdose deaths — almost always alongside opioids, benzodiazepines, or alcohol.
This guide is not an argument against gabapentin. For postherpetic neuralgia and for certain seizure disorders it is a legitimate, often excellent medication, and thousands of people take it every day without a problem. It is an argument for treating it like what it is: a real drug with real effects, worth counting, locking up, and talking about.
What Gabapentin Actually Is
The approved uses are narrower than the prescriptions
Gabapentin is sold as Neurontin, Gralise, and Horizant, and as dozens of generics. Its close cousin pregabalin (Lyrica) behaves similarly enough that clinicians usually discuss them together as "gabapentinoids."
The FDA-approved indications are specific. In adults, gabapentin is approved for postherpetic neuralgia — the lingering nerve pain that can follow shingles. As adjunctive therapy, it is approved for partial-onset seizures in patients three years and older with epilepsy. That is the labeled territory.
The typical dosing shows how far prescription practice can travel from it: for postherpetic neuralgia the label titrates from a single 300 mg dose on day one to 900 mg/day by day three, with a target of 1800 mg/day and clinical studies running up to 3600 mg/day; for seizures in patients twelve and older, 300 mg three times daily, titrated as needed.
Most gabapentin in the United States is not prescribed for either of those things. It is prescribed off-label for low back pain, sciatica, fibromyalgia, restless legs, migraine prevention, and — very commonly — anxiety and insomnia in people in addiction treatment. Prescription volume has climbed steadily since the late 2000s, and the off-label uses are where the evidence gets thin and the doses get high.
It does not work the way people assume
Part of gabapentin's reputation comes from what it doesn't do: the FDA label states plainly that gabapentin "does not exhibit affinity for benzodiazepine, opioid (mu, delta or kappa), or cannabinoid 1 receptor sites." Anyone who has been told "it doesn't touch the same receptors as the drugs you're worried about" has been told something true.
But receptor affinity is not the same as risk. Gabapentin reduces excitatory signaling in the nervous system, and the label itself, in a section most families never see, warns about respiratory depression when gabapentin is used with other central nervous system depressants, including opioids, or in people with underlying breathing problems. A drug can be chemically unrelated to opioids and still deepen the sedation that opioids cause.
Why "Not a Controlled Substance" Is Not the Same as "No Risk"
What the label actually says
The FDA label carries three short sections that answer this question directly, and they are worth quoting because they contradict the reassuring version most families hear.
Under Controlled Substance: "Gabapentin is not a scheduled drug."
Under Abuse: misuse and abuse "have been reported in the postmarketing setting and published literature," most individuals described "had a history of polysubstance abuse," some were "taking higher than recommended doses of gabapentin for unapproved uses," and — critically — "the abuse potential of gabapentin has not been evaluated in human studies." That last sentence is not reassurance. It means nobody has done the study that would let anyone say it is low.
Under Dependence: "There are rare postmarketing reports of individuals experiencing withdrawal symptoms shortly after discontinuing higher than recommended doses of gabapentin used to treat illnesses for which the drug is not approved." The described symptoms were agitation, disorientation, and confusion, resolving after the drug was restarted.
Half the country has already legislated around it
Because the federal schedule never moved, states moved. A 2026 analysis of all 51 U.S. jurisdictions found that 25 jurisdictions (49 percent) enacted policies on gabapentin scheduling or mandatory prescription reporting between 2016 and 2024. Eight classified gabapentin as a Schedule V controlled substance and required prescriber reporting to the state prescription drug monitoring program; seventeen more required PDMP reporting without scheduling it.
Kentucky went first in July 2017, West Virginia in June 2018, and both were watched closely afterward. In Kentucky, Medicaid gabapentin fills fell by a sustained 10.6 prescriptions per 1,000 enrollees per quarter relative to a control state. In West Virginia the drop was immediate — 18.9 per 1,000 enrollees — followed by a smaller sustained decline. In West Virginia, gabapentin-involved fatal overdoses among adults dropped by 0.39 per 100,000 immediately after scheduling, again relative to a state that did not schedule it.
Nothing about that record suggests gabapentin is a crisis on the scale of fentanyl. It suggests something more ordinary and easier to miss: when a medication is treated as harmless, more of it circulates, and more of it ends up in bodies that are already carrying other depressants.
Where the Real Danger Sits: Combinations
The overdose literature has gotten clearer
A 2026 systematic review update in Drugs screened the literature since 2020 and included 100 studies on gabapentinoid misuse, dependence, and overdose. Its conclusion is unusually direct for a review: recent research provides "more compelling evidence that gabapentinoids increase overdose risk, particularly when used with opioids or benzodiazepines." The review also found misuse concentrated in exactly the populations families worry about — people with substance use disorders, people with psychiatric conditions, adolescents, and chronic pain patients.
The FDA label's overdose section says the same thing from the regulatory side: reported symptoms of acute gabapentin overdose include double vision, tremor, slurred speech, drowsiness, altered mental status, dizziness, lethargy, and diarrhea — and "fatal respiratory depression has been reported with gabapentin overdose, alone and in combination with other CNS depressants."
What that looks like in a real drug supply
In November 2026, the Baltimore City Health Department issued an advisory about benzodiazepines appearing in the local illicit supply, based on the state's drug-checking program. In the samples analyzed between April and July, the single most common combination was benzodiazepine plus fentanyl plus cocaine plus gabapentin — 18 of 31 samples.
That is the pattern to hold onto. In a fentanyl-era supply, gabapentin is frequently not the drug someone chose. It is an ingredient, added to a pressed pill or a bag of powder, or taken on top of whatever else is in the person's system, deepening sedation in a body that is already at risk of not breathing.
Naloxone still matters, with one caveat
If someone is unresponsive or breathing slowly, give naloxone and call 911. Naloxone does not reverse gabapentin — it reverses opioids — but in a supply where the two are so often together, the opioid is the thing most likely to stop someone's breathing, and it is the thing you can reverse in minutes. Having naloxone at home is not an overreaction for a household that contains both a gabapentin prescription and any history of opioid use.
Why It Ends Up in So Many Homes in Recovery
The prescription is often the source
A 2026 study interviewed 181 adults recruited through 21 opioid use disorder treatment centers in 23 states — people reporting nonmedical gabapentin use in the past year, plus a smaller comparison group taking it only as prescribed. Among those misusing it, 72.1 percent had a prior prescription for gabapentin and 45.3 percent had a current one. Only 27.7 percent had never had a prescription at all.
How they got it is equally concrete: 50 percent through sharing or trading, 44 percent by buying from a dealer or on the street, and 45.3 percent reported diverting their own gabapentin to someone else. The authors also found that people misusing gabapentin reported higher gabapentin craving than the prescribed-only group — and that many had current prescriptions, which is precisely why they argue for screening and counseling whenever gabapentin is prescribed in addiction treatment.
A second 2026 analysis of the Global Drug Survey (24,954 respondents) found past-year gabapentinoid use at 2.9 percent. Among people who had ever used them, 45.6 percent used their own prescription, 27.2 percent used a non-prescribed source, and 27.2 percent used medication prescribed to someone else.
Read those two studies together and the practical implication is unavoidable: the most common first supply of misused gabapentin is a legal prescription sitting in a house.
The motives are not mysterious
People misuse gabapentin for the effects it has on its own — relaxation, sedation, a break from anxiety, sleep. They also misuse it as a multiplier: to stretch a small amount of opioid, to soften withdrawal when opioids run out, to deepen the effect of benzodiazepines or alcohol, or to self-treat the anxiety and insomnia that are genuinely common in early recovery.
That last motive is the one families should take seriously rather than moralize about. If someone is taking extra gabapentin because they cannot sleep and cannot get help for it, the fix is not a locked box alone. It is a conversation with a prescriber about the actual problem.
What Families Notice First
This is an observation list, not a diagnostic tool. None of these proves misuse, and all of them are worth a calm question.
- Running out early. Refills requested weeks ahead of schedule, or a bottle that is empty when the pharmacy record says it should not be.
- Pills that don't match the count. Especially when the person handles their own supply and the number has never once been checked.
- A new "safe" story. Gabapentin purchased from a friend, "left over from my mom," or traded for something else — always framed as harmless because it is not a narcotic.
- Sedation that doesn't fit the dose. Unusual drowsiness, unsteadiness on stairs, slurred speech, double vision, or confusion — the label's own overdose symptom list, in miniature.
- Use that clusters around the supply. Taking more when opioids are scarce, or on the nights when drinking or benzodiazepines are also involved.
- A second prescriber. Two clinicians, two pharmacies, neither aware of the other.
Stopping Abruptly Is a Bad Plan
Gabapentin is one of those medications where the family's instinct — "just stop it" — is the wrong move.
The label warns that patients with seizure disorders may have increased seizure frequency if gabapentin is discontinued abruptly. It also documents those postmarketing withdrawal reports after sudden discontinuation of higher-than-recommended doses: agitation, disorientation, confusion. Published case literature since then has described a broader syndrome in long-term, high-dose users, which is why clinicians who work with gabapentinoid dependence taper rather than stop.
Practically, that means:
- The prescriber tapers. A gradual reduction over weeks, slower for people on high doses or long durations, with check-ins for sleep, anxiety, and pain.
- Kidney function matters. Gabapentin is cleared almost entirely by the kidneys, and the label requires dose adjustment in reduced renal function. Older adults clear it more slowly, accumulate more of it at the same dose, and are the group most likely to fall.
- Symptom return is not failure. Anxiety, insomnia, and pain often surge during a taper. That is a reason to slow the taper, not to abandon it or to buy more from a friend.
The Other Risks Worth Knowing
- Falls and sedation in older adults. The label notes that the drug is almost entirely renally excreted and that side effects such as peripheral edema and ataxia tend to increase with age.
- Severe hypersensitivity. DRESS — drug reaction with eosinophilia and systemic symptoms — has occurred with gabapentin and, per the label, "some of these reactions have been fatal or life-threatening." Fever, rash, or swollen glands while starting the drug is a reason to stop and get medical care the same day.
- Suicidal thoughts. The label directs monitoring for suicidal behavior and ideation, as with other antiepileptic drugs.
- Pregnancy. Animal data suggest potential fetal harm, and there is a pregnancy exposure registry for antiepileptic drugs; anyone pregnant or planning pregnancy should raise it with the prescriber rather than decide alone.
- Driving. The label tells patients not to drive until they know how the drug affects them.
None of this is a reason to refuse a gabapentin prescription that is working. It is a reason to keep it in the same mental category as the opioids and benzodiazepines: a drug with a dose, a purpose, a side-effect list, and an interaction profile.
What to Do This Week
- Lock it up with everything else. A lockbox that holds the gabapentin, the opioids, and the benzodiazepines together. If it is worth counting, it is worth locking. Our guide on safe medication storage and disposal covers what belongs in there and how to dispose of what does not.
- One prescriber, one pharmacy. Ask directly whether the gabapentin is reported to the state prescription drug monitoring program — in most states it now is, and in eight it is a Schedule V drug.
- Count at every refill. Not as an accusation; as a household habit that applies to everyone, including you.
- Keep naloxone in the house if there is any opioid history at all, and know that it will not reverse gabapentin itself. Here is how to get naloxone.
- Save these numbers. Poison Control at 1-800-222-1222 for exposure questions and dose confusion; 911 for anyone unresponsive or breathing slowly; 988 for suicidal thoughts; the SAMHSA National Helpline at 1-800-662-4357 for treatment referrals.
- Do not flush leftover pills. Use a take-back site or a deactivation pouch, and get them out of the house rather than into the toilet.
Questions to Ask the Prescriber
Bring these to the next appointment, especially if gabapentin was started during detox, in early recovery, or for anxiety rather than for nerve pain:
- What is this being prescribed for, and what is the target dose?
- If it does not work, what is the plan — and how would we stop it?
- What else is being taken that also sedates: opioids, benzodiazepines, alcohol, sleep aids?
- Has kidney function been checked, and does the dose match it?
- Can we consolidate to one pharmacy so the full list is visible?
- What should I watch for at home that would mean calling you?
- Is there a treatment for the underlying problem — anxiety, insomnia, pain — that does not add another sedating medication?
If the answer to the last question is "no, this is the only option," that is worth a second opinion. Anxiety, insomnia, and chronic pain all have evidence-based treatments, and in recovery the choice of which sedating medication to add is a decision, not a default.
Bottom Line
Gabapentin is a real medication with real benefits, and it is not the drug that will kill most people who take it. But "not a narcotic" has quietly become a permission slip — for higher doses, for casual sharing, for a bottle that nobody counts.
The families who do well with it are the ones who treat it like the rest of the medicine cabinet: prescribed by one clinician, filled at one pharmacy, locked in the same box, counted at every refill, and stopped on a schedule instead of overnight. If someone in your home is taking more than the label says, buying it from a friend, or cannot stop without feeling wired and sick, that is not a character problem. It is a clinical one, and it has a clinical answer.
If you are not sure where to start, call the SAMHSA National Helpline at 1-800-662-4357 or search FindTreatment.gov. If someone is struggling right now, 988 is available all day, every day.
Sources
- U.S. Food and Drug Administration — Gabapentin capsules, prescribing information (label sections 5.5, 5.7, 9.1–9.3, 10)
- Ellis MS, et al. Misuse of Pregabalin and Gabapentin: A Second Systematic Review Update. Drugs. 2026
- Characterizing the Relationship Between Nonmedical Use of Gabapentin and Gabapentin Prescribing Among Individuals With Opioid Use Disorder. J Addict Med. 2026
- Non-Prescribed Gabapentinoid Use: Demographic and Behavioural Risk Profiles in a Large International Sample. Drug Alcohol Rev. 2026
- A comprehensive analysis of jurisdiction-specific laws related to scheduling or required prescription drug monitoring of gabapentin in the United States, 2016–2024. Int J Drug Policy. 2026
- Impact of schedule V controlled substance classification of gabapentin on adult gabapentin-involved overdose rates, West Virginia, 2016–2019. Drug Alcohol Depend. 2026
- Decreased Gabapentin Prescription Fills Among Medicaid Enrollees Following State-Level Schedule V Classification in Kentucky and West Virginia. Subst Use Addict J. 2026
- SAMHSA National Helpline
- Poison Control (America's Poison Centers) — 1-800-222-1222
You might also read


